Difference between revisions of "Ondansetron (Zofran)"
(Created page with "==Mechanism of action== 5-HT3 antagonist Category:Emesis prevention") |
|||
| Line 1: | Line 1: | ||
| − | == | + | ==General information== |
| − | 5-HT3 antagonist | + | Class/mechanism: Selective serotonin 5-HT3 receptor antagonist. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.<ref name=insert>[https://www.gsksource.com/gskprm/htdocs/documents/ZOFRAN-ORAL.PDF Ondansetron (Zofran) package insert]</ref><ref>[[Media:Ondansetron.pdf | Ondansetron (Zofran) package insert (locally hosted backup)]]</ref> |
| + | <br>Route: PO | ||
| + | <br>Extravasation: n/a | ||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[http://www.uptodate.com/contents/ondansetron-patient-drug-information Ondansetron (Zofran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ondansetron-patient-drug-information Ondansetron (Zofran) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | Ondansetron ODT, ondansetron oral solution, ondansetron orally disintegrating tablets, zofran ODT, zofran oral solution, zofran orally disintegrating tablets. | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
| + | [[Category:Serotonin 5-HT3 antagonists]] | ||
Revision as of 16:00, 13 October 2014
General information
Class/mechanism: Selective serotonin 5-HT3 receptor antagonist. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
Ondansetron ODT, ondansetron oral solution, ondansetron orally disintegrating tablets, zofran ODT, zofran oral solution, zofran orally disintegrating tablets.